Seung Don Baek, Chung Hee Baek, Ja Seon Kim, So Mi Kim, Ji Hyun Kim, Soon Bae Kim
{"title":"III期慢性肾脏疾病总是进展到终末期肾脏疾病吗?一项为期十年的随访研究。","authors":"Seung Don Baek, Chung Hee Baek, Ja Seon Kim, So Mi Kim, Ji Hyun Kim, Soon Bae Kim","doi":"10.3109/00365599.2011.649045","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Clinically, it may be appropriate to subdivide patients with stage 3 chronic kidney disease (CKD) into two subgroups, as they show different risks for kidney outcomes. This study evaluated the proportion of patients with stage 3 CKD who progressed to stage 4 or 5 CKD over 10 years and independent predictors of progression of renal dysfunction. It sought to validate whether stage 3 CKD patients should be subdivided.</p><p><strong>Material and methods: </strong>This retrospective cohort study enrolled 347 stage 3 CKD patients between January 1997 and December 1999, who were followed up through June 2010. The baseline clinical characteristics and outcomes were compared in patients with stage 3A [45 <estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m(2)] and stage 3B (30 < eGFR <45 ml/min/1.73 m(2)) CKD.</p><p><strong>Results: </strong>Of the 347 patients, 196 (58.2%) were in stage 3A. The only difference in baseline characteristics between stages 3A and 3B patients was the degree of albuminuria. During follow-up, 167 patients (48.1%) did not progress, 60 (17.3%) progressed to stage 4 and 120 (34.6%) progressed to stage 5, with 91 (26.2%) starting dialysis. Multivariate Cox regression analysis showed that macroalbuminuria [(hazard ratio (HR) 3.06, 95% confidence interval (CI) 1.48-2.89, p < 0.001], microalbuminuria (HR 1.99 95% CI 1.04-3.85, p = 0.038), microscopic haematuria (HR 2.07 95% CI 1.48-2.89, p < 0.001) and stage 3B CKD (HR 2.99 95% CI 2.19-4.10, p < 0.001) were independent predictors of progression of renal dysfunction. Stage 3B patients had higher risks of adverse renal and cardiovascular outcomes than stage 3A patients.</p><p><strong>Conclusions: </strong>About half of the patients with stage 3 CKD progressed to stage 4 or 5, as assessed by eGFR, over 10 years. Degree of albuminuria, stage 3 subgroup and microscopic haematuria were important risk factors for progression of stage 3 CKD. It would be appropriate to divide the present stage 3 CKD into two subgroups.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":" ","pages":"232-8"},"PeriodicalIF":0.0000,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.649045","citationCount":"23","resultStr":"{\"title\":\"Does stage III chronic kidney disease always progress to end-stage renal disease? A ten-year follow-up study.\",\"authors\":\"Seung Don Baek, Chung Hee Baek, Ja Seon Kim, So Mi Kim, Ji Hyun Kim, Soon Bae Kim\",\"doi\":\"10.3109/00365599.2011.649045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Clinically, it may be appropriate to subdivide patients with stage 3 chronic kidney disease (CKD) into two subgroups, as they show different risks for kidney outcomes. This study evaluated the proportion of patients with stage 3 CKD who progressed to stage 4 or 5 CKD over 10 years and independent predictors of progression of renal dysfunction. It sought to validate whether stage 3 CKD patients should be subdivided.</p><p><strong>Material and methods: </strong>This retrospective cohort study enrolled 347 stage 3 CKD patients between January 1997 and December 1999, who were followed up through June 2010. The baseline clinical characteristics and outcomes were compared in patients with stage 3A [45 <estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m(2)] and stage 3B (30 < eGFR <45 ml/min/1.73 m(2)) CKD.</p><p><strong>Results: </strong>Of the 347 patients, 196 (58.2%) were in stage 3A. The only difference in baseline characteristics between stages 3A and 3B patients was the degree of albuminuria. During follow-up, 167 patients (48.1%) did not progress, 60 (17.3%) progressed to stage 4 and 120 (34.6%) progressed to stage 5, with 91 (26.2%) starting dialysis. Multivariate Cox regression analysis showed that macroalbuminuria [(hazard ratio (HR) 3.06, 95% confidence interval (CI) 1.48-2.89, p < 0.001], microalbuminuria (HR 1.99 95% CI 1.04-3.85, p = 0.038), microscopic haematuria (HR 2.07 95% CI 1.48-2.89, p < 0.001) and stage 3B CKD (HR 2.99 95% CI 2.19-4.10, p < 0.001) were independent predictors of progression of renal dysfunction. Stage 3B patients had higher risks of adverse renal and cardiovascular outcomes than stage 3A patients.</p><p><strong>Conclusions: </strong>About half of the patients with stage 3 CKD progressed to stage 4 or 5, as assessed by eGFR, over 10 years. Degree of albuminuria, stage 3 subgroup and microscopic haematuria were important risk factors for progression of stage 3 CKD. It would be appropriate to divide the present stage 3 CKD into two subgroups.</p>\",\"PeriodicalId\":21543,\"journal\":{\"name\":\"Scandinavian Journal of Urology and Nephrology\",\"volume\":\" \",\"pages\":\"232-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3109/00365599.2011.649045\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Urology and Nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/00365599.2011.649045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2012/5/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Urology and Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/00365599.2011.649045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/5/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 23
摘要
目的:临床上,将3期慢性肾脏疾病(CKD)患者细分为两个亚组可能是合适的,因为他们表现出不同的肾脏结局风险。本研究评估了3期CKD患者在10年内进展为4期或5期CKD的比例以及肾功能障碍进展的独立预测因素。它试图验证3期CKD患者是否应该细分。材料和方法:这项回顾性队列研究在1997年1月至1999年12月期间招募了347例3期CKD患者,随访至2010年6月。比较3A期患者的基线临床特征和结局[45]结果:347例患者中,196例(58.2%)为3A期。3A期和3B期患者基线特征的唯一差异是蛋白尿程度。在随访期间,167例患者(48.1%)没有进展,60例(17.3%)进展到4期,120例(34.6%)进展到5期,91例(26.2%)开始透析。多因素Cox回归分析显示,大量白蛋白尿(风险比(HR) 3.06, 95%可信区间(CI) 1.48 ~ 2.89, p < 0.001)、微量白蛋白尿(HR 1.99 95% CI 1.04 ~ 3.85, p = 0.038)、显微血尿(HR 2.07 95% CI 1.48 ~ 2.89, p < 0.001)和3B期CKD (HR 2.99 95% CI 2.19 ~ 4.10, p < 0.001)是肾功能障碍进展的独立预测因子。3B期患者的肾脏和心血管不良结局风险高于3A期患者。结论:根据eGFR评估,大约一半的3期CKD患者在10年内进展到4期或5期。蛋白尿程度、3期亚组和显微镜下血尿是3期CKD进展的重要危险因素。将目前的3期CKD分为两个亚组是合适的。
Does stage III chronic kidney disease always progress to end-stage renal disease? A ten-year follow-up study.
Objective: Clinically, it may be appropriate to subdivide patients with stage 3 chronic kidney disease (CKD) into two subgroups, as they show different risks for kidney outcomes. This study evaluated the proportion of patients with stage 3 CKD who progressed to stage 4 or 5 CKD over 10 years and independent predictors of progression of renal dysfunction. It sought to validate whether stage 3 CKD patients should be subdivided.
Material and methods: This retrospective cohort study enrolled 347 stage 3 CKD patients between January 1997 and December 1999, who were followed up through June 2010. The baseline clinical characteristics and outcomes were compared in patients with stage 3A [45
Results: Of the 347 patients, 196 (58.2%) were in stage 3A. The only difference in baseline characteristics between stages 3A and 3B patients was the degree of albuminuria. During follow-up, 167 patients (48.1%) did not progress, 60 (17.3%) progressed to stage 4 and 120 (34.6%) progressed to stage 5, with 91 (26.2%) starting dialysis. Multivariate Cox regression analysis showed that macroalbuminuria [(hazard ratio (HR) 3.06, 95% confidence interval (CI) 1.48-2.89, p < 0.001], microalbuminuria (HR 1.99 95% CI 1.04-3.85, p = 0.038), microscopic haematuria (HR 2.07 95% CI 1.48-2.89, p < 0.001) and stage 3B CKD (HR 2.99 95% CI 2.19-4.10, p < 0.001) were independent predictors of progression of renal dysfunction. Stage 3B patients had higher risks of adverse renal and cardiovascular outcomes than stage 3A patients.
Conclusions: About half of the patients with stage 3 CKD progressed to stage 4 or 5, as assessed by eGFR, over 10 years. Degree of albuminuria, stage 3 subgroup and microscopic haematuria were important risk factors for progression of stage 3 CKD. It would be appropriate to divide the present stage 3 CKD into two subgroups.